Clinical characteristics at baseline for the PACEMAN-HF study
| PACEMAN-HF | All n=72 | IG n=32 | CG n=40 | P value |
| Male gender | 68 | 66 | 70 | n.s. |
| Age (mean±SD) | 75±8 | 75±8 | 76±7 | n.s. |
| NYHA I | 0 | 0 | 0 | |
| NYHA II | 26 | 38 | 18 | n.s. |
| NYHA III | 74 | 63 | 83 | |
| Atrial fibrillation | 61 | 47 | 73 | p<0.05 |
| Diabetes mellitus | 40 | 34 | 45 | n.s. |
| COPD | 18 | 13 | 23 | n.s. |
| Hypertension | 50 | 56 | 45 | n.s. |
| CAD | 29 | 28 | 30 | n.s. |
| Beta-blockers | 92 | 97 | 88 | n.s. |
| RAS-blockade | 74 | 69 | 78 | n.s. |
| MRA | 31 | 31 | 30 | n.s. |
All numbers presented as per cent unless otherwise noted.
CAD, coronary artery disease; CG, control group; COPD, chronic obstructive pulmonary disease; IG, intervention group; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; RAS-blockade, renin-angiotensin system blockade (angiotensin converting enzyme inhibitor or angiotensin receptor blocker); n.s., non-significant.